A Phase 1/2 Randomized, Observer-blinded, Multi-country Study to Evaluate Safety and Immunogenicity of Investigational Adjuvanted Human Papillomavirus Vaccine in Females (16 to 26 Years of Age)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Human-papillomavirus-adjuvanted-vaccine-GlaxoSmithKline/Xiamen-Innovax-Biotech (Primary) ; V 503
Indications Cervical intraepithelial neoplasia
Focus Adverse reactions; First in man; Pharmacodynamics
Acronyms HPV9-AS04-001
Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

03 Feb 2025 Primary endpoints updated.
13 Nov 2024 Status changed from active, no longer recruiting to completed.
25 May 2024 This trial has been completed in Poland (Global end date: 23 Feb 2024).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com